Questions and Answers
What is the generic name and class of Jardiance?
Empagliflozin and it is an SGLT2.
Is Jardiance effective in lowering the risk for cardiovascular death?
True
What did Jardiance achieve in the EMPA-REG OUTCOME trial?
It achieved superiority for the primary cardiovascular endpoint and a significant reduction in cardiovascular death.
What is the indication for Jardiance?
Signup and view all the answers
Can Jardiance be used in patients with a history of serious hypersensitivity to the drug?
Signup and view all the answers
Some common side effects of Jardiance include dehydration, dizziness, _____, and nausea.
Signup and view all the answers
What is the starting dose for Jardiance?
Signup and view all the answers
How often is Jardiance taken?
Signup and view all the answers
What is the mechanism of action of Jardiance?
Signup and view all the answers
What is one important benefit of Jardiance indicated at 24 weeks?
Signup and view all the answers
A lower dose of insulin may be required when Jardiance is used with sulfonylureas?
Signup and view all the answers
What kind of trial was conducted to study Jardiance?
Signup and view all the answers
Hypoglycemia rates are lower when Jardiance is used with insulin.
Signup and view all the answers
What is the coverage status of Jardiance?
Signup and view all the answers
Jardiance is recommended for patients with type 1 diabetes.
Signup and view all the answers
Can Jardiance be taken with other common cardiovascular medicines?
Signup and view all the answers
Study Notes
Jardiance Overview
- Jardiance, generically known as empagliflozin, belongs to the SGLT2 inhibitor class.
Efficacy
- Proven to lower the risk of cardiovascular (CV) death in adults with type 2 diabetes (T2D) and known cardiovascular disease.
Clinical Data
- Demonstrated superiority for primary CV endpoints and significant reduction in CV death in high-risk T2D patients.
- Results from the EMPA-REG OUTCOME trial published in NEJM and presented at a major diabetes conference.
Indication
- Prescribed to lower blood sugar in adults with T2D alongside diet and exercise.
- Also indicated to reduce the risk of cardiovascular death in patients with T2D with existing cardiovascular conditions.
Safety
- Contraindicated for patients with serious hypersensitivity to empagliflozin and severe renal impairment, including end-stage renal disease or those on dialysis.
Side Effects
- Common side effects include dehydration, dizziness, lightheadedness, weakness, yeast infections, low blood sugar, nausea, and upper respiratory infections.
Dosing
- Available in 10 mg and 25 mg doses; no dose adjustments needed for patients with eGFR ≥ 45 mL/min.
Administration
- Taken once daily, with or without food, preferably in the morning.
Mechanism of Action
- Empagliflozin is an SGLT2 inhibitor which prevents glucose reabsorption in the kidneys, promoting glucose excretion in urine.
Other Important Information
- Demonstrates efficacy in reducing A1C levels at 24 weeks as monotherapy.
Hypoglycemia Risks
- Increased hypoglycemia rates when co-administered with insulin or sulfonylureas.
Insurance Coverage
- Jardiance holds extensive commercial insurance coverage.
Recommendations
- Not advised for type 1 diabetes patients or for treating diabetic ketoacidosis.
Combination with Other Medications
- Can be safely combined with various cardiovascular medications such as statins, beta blockers, ACE inhibitors, and diuretics but does not substitute for these treatments.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Explore the key aspects of Jardiance (empagliflozin), a medication from the SGLT2 inhibitor class. Learn about its efficacy in reducing cardiovascular death in adults with type 2 diabetes and the clinical data supporting its use. This quiz covers indications, safety concerns, and common side effects associated with Jardiance.
